Enovis (NYSE:ENOV) Price Target Lowered to $47.00 at Citizens Jmp

Enovis (NYSE:ENOV) had its target price cut by equities researchers at Citizens Jmp from $55.00 to $47.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The firm presently has a “market outperform” rating on the stock. Citizens Jmp’s target price indicates a potential upside of 127.49% from the stock’s current price.

Several other research analysts have also commented on ENOV. Wall Street Zen lowered shares of Enovis from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Wells Fargo & Company decreased their target price on Enovis from $40.00 to $39.00 and set an “overweight” rating for the company in a research note on Friday, August 7th. UBS Group reaffirmed a “buy” rating and set a $51.00 target price (up from $50.00) on shares of Enovis in a report on Tuesday, July 28th. BMO Capital Markets set a $27.00 target price on Enovis in a report on Tuesday. Finally, Weiss Ratings upgraded Enovis from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Tuesday, July 21st. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $41.12.

Enovis Stock Performance

Shares of Enovis stock opened at $20.66 on Wednesday. The company has a debt-to-equity ratio of 0.84, a quick ratio of 1.00 and a current ratio of 1.98. Enovis has a 1 year low of $19.14 and a 1 year high of $34.28. The firm’s 50-day simple moving average is $25.65 and its 200-day simple moving average is $24.27. The firm has a market cap of $1.19 billion, a PE ratio of -1.07 and a beta of 1.32.

Enovis (NYSE:ENOV) last announced its quarterly earnings data on Thursday, August 6th. The company reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.85 by $0.05. Enovis had a positive return on equity of 12.03% and a negative net margin of 47.96%.The firm had revenue of $582.78 million for the quarter, compared to analysts’ expectations of $581.84 million. During the same quarter in the prior year, the firm posted $0.79 earnings per share. Enovis’s revenue for the quarter was up 3.2% compared to the same quarter last year. Enovis has set its FY 2026 guidance at 3.520-3.730 EPS. Equities analysts forecast that Enovis will post 3.15 earnings per share for the current fiscal year.

Insider Buying and Selling at Enovis

In other news, insider Oliver Engert acquired 1,200 shares of the company’s stock in a transaction that occurred on Thursday, June 11th. The shares were acquired at an average price of $21.62 per share, with a total value of $25,944.00. Following the acquisition, the insider directly owned 51,840 shares in the company, valued at approximately $1,120,780.80. The trade was a 2.37% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Over the last 90 days, insiders have bought 3,200 shares of company stock valued at $69,864. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. AQR Capital Management LLC raised its holdings in shares of Enovis by 12.5% during the first quarter. AQR Capital Management LLC now owns 63,671 shares of the company’s stock valued at $2,363,000 after buying an additional 7,072 shares during the last quarter. Goldman Sachs Group Inc. boosted its position in shares of Enovis by 37.6% during the first quarter. Goldman Sachs Group Inc. now owns 267,617 shares of the company’s stock worth $10,226,000 after buying an additional 73,116 shares during the period. Empowered Funds LLC grew its holdings in Enovis by 13.0% in the 1st quarter. Empowered Funds LLC now owns 6,515 shares of the company’s stock worth $249,000 after buying an additional 749 shares in the last quarter. EverSource Wealth Advisors LLC grew its holdings in Enovis by 125.4% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,271 shares of the company’s stock worth $40,000 after buying an additional 707 shares in the last quarter. Finally, Amundi increased its position in Enovis by 24,405.0% in the 2nd quarter. Amundi now owns 9,802 shares of the company’s stock valued at $328,000 after acquiring an additional 9,762 shares during the period. Institutional investors own 98.45% of the company’s stock.

Key Enovis News

Here are the key news stories impacting Enovis this week:

• Positive Sentiment: The proposed acquisition would add robotic automation to Enovis’ ASTRA™ enabling-technology platform, expanding its portfolio in surgical precision, workflow efficiency and patient-outcome technologies. Enovis Invests in Innovation with Binding Offer to Acquire eCential Robotics
• Positive Sentiment: Management is positioning eCential’s technology as a growth opportunity in the surgical robotics market and plans to bring its surgical robot to a broader commercial market through Enovis’ platform and distribution capabilities. Enovis to acquire eCential Robotics for €155 million
• Neutral Sentiment: The transaction remains a binding offer rather than a completed acquisition, so closing conditions, integration plans and the eventual financial contribution from eCential remain important upcoming catalysts. eCential Robotics Announces Binding Offer from Enovis
• Neutral Sentiment: Enovis is scheduled to participate in the Wells Fargo Healthcare Conference on September 8, where investors may seek additional details on the acquisition, funding and the company’s robotics strategy. Enovis to Participate in the 2026 Wells Fargo Healthcare Conference
• Negative Sentiment: Despite the strategic appeal, investors reacted negatively to the roughly $180 million purchase commitment, apparently weighing the near-term capital deployment and execution risk against the longer-term robotics opportunity. Shares fell sharply and approached their 52-week low. Enovis drops on binding offer to acquire eCential Robotics

About Enovis

Enovis is a global medical technology company focused on advancing the field of musculoskeletal health. Formed through the separation of the MedTech business from Colfax Corporation in 2021, Enovis brings together a portfolio of specialized products and services designed to address conditions affecting the foot and ankle, hand and wrist, sports medicine, joint repair, biologics and rehabilitation.

The company’s flagship offerings include minimally invasive implants and instrumentation for foot and ankle surgery under the Treace Medical Concepts brand, focal joint resurfacing implants through Arthrosurface, and synthetic bone graft substitutes marketed as NovaBone.